



Contact:

Dr. Misha Plam, President & CEO

(303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

Dr. John P. Mayer, recognized leader in peptide drug discovery, joins AmideBio's Science Advisory Board

BOULDER, CO, December 13, 2012 – AmideBio, LLC, a privately held biopharmaceutical company that develops novel recombinant manufacturing processes for peptides and proteins, announced today that John P. Mayer, Ph.D., Senior Research Scientist at Indiana University and previously a leader in peptide drug discovery at Eli Lilly and Company and Amgen Inc., has joined AmideBio's Scientific Advisory Board. Dr. Mayer will play a key role in advising the Company on the design and development of specific peptide projects.

AmideBio's President & CEO Dr. Misha Plam commented, "Dr. Mayer has great expertise in our platform technology and its application to drug discovery. He will guide us toward industry-leading solutions for the discovery and development of drugs to treat some of the most challenging disease targets, with a special focus on Alzheimer's disease and diabetes. We are enormously pleased that a scientist of Dr. Mayer's stature and experience has chosen to join us."

Dr. Mayer added, "I'm very excited about the potential of the AmideBio technology to revolutionize the discovery and development of life changing, peptide-based medicines."

Prior to recently joining the department of chemistry at Indiana University, Dr. Mayer spent 14 years as a drug discovery scientist at Eli Lilly and Co. where he initially organized and led the Peptide Therapeutics group from 2000-2012. During this time he made a number of important contributions to the discovery of several diabetes and cancer therapeutic candidates currently in clinical development.

Prior to joining Eli Lilly, Dr. Mayer established and led the Peptide Chemistry group at Amgen's research laboratories in Boulder, Colorado, which supports all of Amgen's peptide therapeutic projects. Dr. Mayer has authored and co-authored more than 50 research articles and is the listed inventor or co-inventor on a number of key patents. Dr. Mayer obtained his doctorate in medicinal chemistry from Purdue University followed by two years conducting postdoctoral research at Eli Lilly on the total synthesis of human insulin and insulin related peptides under the direction of Dr. Richard DiMarchi.

About AmideBio:

AmideBio, based in Boulder, CO, is an early-stage biotechnology company that has developed a unique technology for producing peptides and proteins, especially ones that

previously were difficult to manufacture in large quantities. The Company is expanding its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing, and internal research and development of novel targets for biotherapeutics to treat inflammatory and neurodegenerative diseases. The AmideBio BioPure™ process provides the research community with some of the purest peptide-derived products available to date, including amyloid-beta, a protein that may be a key player in Alzheimer's disease. The Company's platform offers an economical and environmentally sustainable process for large-scale production, with the aim of providing patients with high quality, lower-cost medications.

- ENDS -